Gelonghui, January 10 | HiCisco (002653.SZ) announced that the company recently received the “Notice of Acceptance” issued by the State Drug Administration, which is an HSK16149 capsule.
HSK16149 developed by the company is a new oral gamma-aminobutyric acid (GABA) analog with independent intellectual property rights. hSK16149 can bind to voltage-sensitive calcium channel α2delta receptors in the central nervous system to reduce calcium ion flow in voltage-dependent calcium channels in the central nervous system, thereby reducing the release of excitatory neurosubstances such as glutamate, noradrenaline (NE), and P substances, and has analgesic, anticonvulsant, and anxiolytic activity. The α2delta subunit has been identified as primary targets for analgesic effects of pregabalin and gabapentin (two drugs currently marketed to treat chronic neuropathic pain). Compared with pregabalin, HSK16149 binds more strongly to α2delta subreceptors and is expected to have better analgesic efficacy. It is expected to provide a safe and effective new option for the treatment of pathological pain in the central nervous system.